Phosphofructokinase: A Potential Drug Target Or Biomarker (G5213)

Target Name: PFKM

NCBI ID: G5213

Phosphofructokinase: A Potential Drug Target Or Biomarker

Phosphofructokinase (PK) is a protein that plays a crucial role in cellular metabolism, particularly in the production of ATP energy molecule. PFKM, a muscle-type isoform (isoform 1) of the ATP-dependent 6-phosphofructokinase, is an enzyme that catalyzes the conversion of ADP and phosphate to ATP. PFKM is often used as a drug target or biomarker in various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders.

PFKM is a member of the P21 subfamily of the ATP-dependent protein kinase (ATPK) family. This family is characterized by the presence of a catalytic domain, a nucleotide-binding domain, and a carboxylic acid side chain. PFKM is similar to other members of the P21 family, such as P21 and P23, in that it contains a nucleotide-binding domain that is critical for its catalytic activity.

PFKM is localized to the endoplasmic reticulum (ER) and is predominantly found in muscle fibers, where it is involved in the production of ATP using the ATP-dependent 6-phosphofructokinase pathway. PFKM is a key enzyme in the production of ATP, which is essential for various cellular processes, including muscle contraction and protein synthesis.

PFKM has been identified as a potential drug target or biomarker due to its involvement in various diseases. One of the main reasons for its potential as a drug target is its involvement in the production of ATP, which is a crucial molecule for cellular metabolism and growth . Attempts to inhibit PFKM have been shown to have therapeutic effects in various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders.

In cancer, PFKM has been shown to play a negative role in the regulation of cell growth and division. In addition, inhibition of PFKM has been shown to enhance the efficacy of chemotherapy drugs in various types of cancer. This is because PFKM is involved in the production of ATP, which is a crucial energy source for cancer cells. By inhibiting the production of ATP, PFKM can inhibit the growth and survival of cancer cells.

In cardiovascular diseases, PFKM has been shown to be involved in the regulation of cardiac muscle contractions. This is important because alterations in PFKM activity can affect cardiac muscle function and contribute to the development of various cardiovascular diseases, such as heart failure and arrhythmias. Therefore , inhibition of PFKM has been shown to be a potential therapeutic approach for treating cardiovascular diseases.

In neurodegenerative disorders, PFKM has been shown to play a positive role in the regulation of neuronal function and survival. These disorders are characterized by the progressive loss of neurons and their associated proteins, which can lead to a range of symptoms, including muscle weakness and dysfunction. Therefore, manipulation of PFKM activity has been shown to be a potential therapeutic approach for treating neurodegenerative disorders.

In conclusion, PFKM is a protein that plays a crucial role in cellular metabolism, particularly in the production of ATP energy molecules. Its involvement in the regulation of ATP production makes it an attractive target for drug development. The potential therapeutic effects of PFKM have been shown in various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. Therefore, PFKM is a potential drug target or biomarker that should be further investigated for its therapeutic potential.

Protein Name: Phosphofructokinase, Muscle

Functions: Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis

More Common Targets